DC101 enhances the anti-tumour response of a cancer vaccine targeting neu (the murine equivalent of HER2) gene expression in an immunocompetent mouse model of tumours driven by over expression of neu [10,155]. The gene discussed is ERBB2; the disease is neoplasm.